Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2
inhibitor type, placebo-controlled trial, - a Phase III study. Primary objective of the study
is to investigate the impact of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on
clinical endpoints in patients hospitalized with acute/decompensated HF.
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Warsaw
Collaborators:
Autonomous Public Specialist Western John Paul II Hospital in Grodzisk Mazowiecki Jerzy Popiełuszko Bielański Hospital in Warsaw John Paul II Specialist Hospital in Kraków Ludwik Rydygier Regional Polyclinical Hospital in Toruń Medical University of Gdańsk Medical University of Graz Medical University of Silesia in Katowice Medical University of Vienna Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz Poznan University of Medical Sciences Regional Polyclinical Hospital in Kielce University Clinical Center of the Medical University of Warsaw University Clinical Hospital Military Medical Academy, Central Veterans Hospital in Łódź University Teaching Hospital in Białystok